Objectives We sought to evaluate the safety and efficacy of bivalirudin compared with glycoprotein IIb/IIIa inhibitors (GPI) in diabetic patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).
Patients with diabetes mellitus and acute coronary syndromes-both non-ST-segment elevation acute myocardial infarction (NSTEMI) (1) and ST-segment elevation acute myocardial infarction (STEMI) (2)-are at greater risk of death and myocardial infarction compared with patients without diabetes mellitus. Previous studies have suggested that glycoprotein IIb/IIIa inhibitors (GPI) improve the prognosis in diabetic patients, including those undergoing percutaneous coronary intervention (PCI) for stable ischemic heart disease (3, 4) , for NSTEMI (1, 5) and STEMI (6) . However, most of the evidence favoring GPI in STEMI patients undergoing primary PCI was established in the era before thienopyridines (7) . A recent study demonstrated that the GPI abciximab does not reduce infarct size or improve clinical outcomes in STEMI patients within 24 h of symptom onset treated with dual antiplatelet therapy, whether diabetic or not (8) .
Bivalirudin is a direct thrombin inhibitor with antiischemic properties and favorable bleeding event rates when used in elective PCI (9) , in acute coronary syndromes patients (10) and STEMI patients treated with primary PCI (11) . However, the impact of bivalirudin in high-risk patients with diabetes and STEMI undergoing PCI has not been reported. Therefore, we evaluated the safety and efficacy of bivalirudin in comparison with treatment with heparin plus GPI in diabetic patients with STEMI undergoing primary PCI from the randomized, prospective multicenter HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial.
Methods
Patient population and study protocol. The HORIZONS-AMI study design has been previously described in detail (11, 12) . In summary, the HORIZONS-AMI trial was a prospective, open-label, randomized, multicenter trial in which 3,602 patients with STEMI presenting within 12 h of symptom onset and undergoing a primary PCI management strategy were randomized 1:1 to bivalirudin alone versus unfractionated heparin plus a GPI (the control group). After angiography, eligible patients were randomized again in a 3:1 ratio to either TAXUS Express paclitaxel-eluting stents or otherwise identical uncoated Express bare-metal stents (Boston Scientific, Natick, Massachusetts). The study was approved by the institutional review board or ethics committee at each participating center, and all patients signed informed consent.
Patient eligibility criteria has also been described previously (11) (12) (13) . In summary, consecutive patients Ն18 years of age with symptom onset within 12 h of duration and ST-segment elevation of Ն1 mm in Ն2 contiguous leads, new left bundle branch block, or true posterior myocardial infarction were considered for enrollment. Principal exclusion criteria included contraindications to any of the study medications; prior administration of fibrinolytic therapy, bivalirudin, GPI, low molecular weight heparin, or fondaparinux for the present admission (prior unfractionated heparin was allowed); current use of coumadin; history of bleeding diathesis, conditions predisposing to hemorrhagic risk, or refusal to receive blood transfusions; stroke or transient ischemic attack within 6 months or any permanent neurological deficit; recent or known platelet count Ͻ100,000 cells/mm 3 or hemoglobin Ͻ10 g/dl; planned elective surgical procedure that would necessitate interruption of thienopyridines during the first 6 months after enrollment; coronary stent implantation within 30 days; and noncardiac comorbid conditions with life expectancy Ͻ1 year or that might result in protocol noncompliance.
Endpoints and statistical analysis.
The 2 primary endpoints of the HORIZONS-AMI trial were major bleeding (not related to coronary artery bypass grafting) and net adverse clinical events (NACE), defined as the combination of major bleeding or major adverse cardiovascular events (MACE). Major adverse cardiovascular events comprised death, reinfarction, target vessel revascularization for ischemia, or stroke. The endpoint definitions have been detailed elsewhere (12) . Bleeding was adjudicated according to the protocol definition (11) (14) . Noncardiac death was defined as a death not due to cardiac causes, including bleeding-related death. All primary and secondary endpoint events were adjudicated by a clinical events committee using original source documents, blinded to treatment assignment.
Diabetes was defined as a history of hyperglycemia managed by insulin, oral hypoglycemic agents, or diet. Categorical outcomes were compared by chi-square test or Fisher exact test. Continuous variables were compared by means of the Wilcoxon rank-sum test. Time-to-event outcomes, determined with Kaplan-Meier methods, were compared by the log-rank test. Independent correlates of 30-day and 1-year mortality in the entire randomized population and in the cohort undergoing primary PCI were determined by Cox proportional hazards regression.
Results
Patients and procedures. Of 3,602 patients with STEMI undergoing primary PCI and enrolled in the HORIZONS-AMI trial, 593 patients (16.5%) had diabetes mellitus. This included 159 (26.8%) treated with insulin, 322 (54.3%) treated with oral medications without insulin, and 107 (18.0%) treated with diet alone. Of those, 281 patients were randomized to anticoagulant treatment with bivalirudin, and 312 were randomized to heparin plus a GPI. The baseline features and procedural data in patients randomized to bivalirudin versus heparin plus a GPI were well-matched in the diabetic and nondiabetic cohort (Tables 1 and 2 ). Among patients with diabetes, there were no significant differences in management strategy after coronary angiography: PCI was subsequently performed in 92.2% of the bivalirudin-treated group and in 91.7% of the heparin plus GPI group (p ϭ 0.82), coronary artery bypass grafting without PCI was subsequently performed in 2.1% versus 3.5%, respectively (p ϭ 0.31), and medical management was subsequently performed in 5.7 versus 4.8%, respectively (p ϭ 0.63). Thienopyridine use before admission was slightly higher in the diabetic patients randomized to heparin plus GPI, and the percentage of angiotensinconverting enzyme inhibitors or angiotensin receptor blockers at discharge was slightly lower in nondiabetic patients randomized to bivalirudin (Table 2) .
Clinical outcomes in diabetic and nondiabetic patients.
Among the diabetic cohort, there were no significant differences in the rates of NACE, MACE, all-cause mortality, or major bleeding events in patients assigned to bivalirudin versus heparin plus GPI at 30 days (Table 3) . However, bivalirudin treatment was associated with a significantly reduced 30-day rate of cardiac death (2.1% vs. 5.5%, p ϭ 0.04) and stroke (0% vs. 2.0%, p ϭ 0.02). Noncardiac mortality was higher at 30 days with bivalirudin, however (1.4% vs. 0%, p ϭ 0.05), and as such there was no significant difference in all-cause mortality between the 2 therapies. At 1 year, of the rate of cardiac mortality in diabetic patients was significantly reduced with bivalirudin compared with heparin plus GPI (2.5% vs. 7.1%, p ϭ 0.01), and the difference in noncardiac mortality was no longer significant (2.2% vs. 0.7%, p ϭ 0.12). All-cause mortality at 1 year occurred in 4.7% of diabetic patients treated with bivalirudin compared with 7.8% treated with heparin plus GPI (p ϭ 0.13). There were no significant differences in the 1-year rates of NACE, MACE, and major bleeding according to assigned treatment (Fig. 1) . Among nondiabetic patients, randomization to bivalirudin resulted in a significant reduction of NACE (at 30 days: 8.8%
vs. 11.9%, p ϭ 0.005; at 1 year: 14.7% vs. 17.5%, p ϭ 0.03) and major bleeding (at 30 days: 4.7% vs. 8.6%, p Ͻ 0.0001; at 1 year 5.3% vs. 9.0%, p Ͻ 0.0001), with nonsignificant differences in MACE (Fig. 1, Table 3 ).
Further analysis of the diabetic patients according to insulin-treated and noninsulin-treated cohorts did not reveal any significant differences of bivalirudin or heparin plus GP IIb/IIIa treatment for NACE or major adverse clinical or bleeding events, whereas there was a significant advantage in favor of bivalirudin treatment among insulin-treated patients with regard to cardiac death at 1 year (1.4% vs. 9.4%, p ϭ 0.04) (Fig. 2, Table 4 ).
Formal interaction testing demonstrated that the favorable effects of bivalirudin compared with heparin plus GPI in reducing the 1-year rates of major bleeding, NACE, all-cause mortality, and cardiac mortality in the entire study population (12) were independent of diabetic (Table 5) , and interaction testing for an effect of diabetic status on stent thrombosis by randomization was negative (p ϭ 0.93). There were also no significant differences in the rate of stent thrombosis between the 2 treatment arms when the diabetic patients were further separated into insulin-treated or non-insulin-treated groups (Table 5) .
Discussion
Diabetic patients presenting with STEMI have a substantially greater incidence of early and late death or myocardial infarction compared with nondiabetic subjects (15-17).
With contemporary interventional approaches, the procedural success rate of primary PCI in diabetic patients with STEMI is equivalent to nondiabetic patients, as reinforced in the present report (16, 18) . However, diabetic patients with STEMI compared with nondiabetic patients are less likely to achieve normal myocardial perfusion (as measured by reduced restoration of normal angiographic myocardial blush and ST-segment resolution, and a greater incidence of distal embolization), which has been associated with higher mortality (2, 18, 19) . Glycoprotein IIb/IIIa inhibitors might improve myocardial perfusion and survival (20, 21) , particularly in patients with diabetes. In the ADMIRAL (Abciximab before Direct angioplasty and stenting in Myocardial Infarction Regarding Acute and Long-term follow-up) trial (6), the 6-month rates of mortality and target vessel revascularization after primary stenting were reduced in the 53 diabetic patients randomized to abciximab versus placebo (mortality: 0% vs. 16.7%, p ϭ 0.02; target vessel revascularization: 3.7% vs. 37.5%, p ϭ 0.046). However, this result was not reproduced in the larger CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial with 346 diabetic patients enrolled (22, 23) . A meta-analysis based on individual specific data from the ISAR-2 (Intracoronary Stenting and Antithrombotic Regimen-2) (24), ADMIRAL (6), and ACE (Abciximab-Carbostent Evaluation) (25) studies including 183 diabetic patients reported that death and reinfarction were significantly lower in diabetic patients treated with abciximab compared with UFH alone (26) . We have previously reported that patients randomized to bivalirudin rather than heparin plus GPI in the HORIZONS-AMI trial benefitted from a pronounced reduction in bleeding events, along with NACE and allcause and cardiac mortality (11, 27) . However, a recent meta-regression analysis suggested that the benefits from adjunctive GPI in improving survival are most evidenced in high-risk patients, such as those with diabetes mellitus (28) . With this background, the current report in 593 diabetic patients enrolled in the HORIZONS-AMI trial represents the largest analysis of diabetic STEMI patients treated by contemporary primary PCI to date and demonstrates that bivalirudin compared with heparin plus GPI significantly reduces cardiac mortality in the high-risk diabetic cohort as well as patients without diabetes.
Although cardiac mortality and stroke were reduced in diabetic patients treated with bivalirudin rather than heparin plus GPI, total mortality, major bleeding, and NACE were not significantly reduced in the diabetic cohort with bivalirudin. However, interaction testing demonstrated that the relative reductions in bleeding, NACE, and all-cause and cardiac mortality with bivalirudin compared with heparin plus GPI were not significantly different in the diabetic and nondiabetic groups. Given that subgroups are inherently underpowered (29) , the most appropriate interpretation of these data is that the overall benefits with bivalirudin seen in the main trial seem to apply to patients both with and without diabetes. However, we cannot exclude a modest difference in the relative effect of bivalirudin versus heparin plus GPI in patients with versus without diabetes. Moreover, previous studies have suggested a higher rate of stent thrombosis in diabetic patients, particularly those insulin-treated (30, 31) . In the present analysis the overall rate of stent thrombosis in the diabetic subgroup was comparable in patients treated with bivalirudin or those treated with heparin plus GPI.
In the HORIZONS-AMI trial, study medications were most commonly initiated in the catheterization laboratory. Previous analyses suggest that an "upstream" pre-catheterization Subgroup analyses: hazard ratios with 95% confidence intervals for the 1-year rates of NACE, major bleeding not related to CABG, MACE, and cardiac death, in the overall study population and according to diabetic status, for insulin-treated and non-insulin-treated diabetic patients, nondiabetic patients, and overall study population. *For cardiac mortality among insulin-treated diabetic patients, the 95% confidence interval of the hazard ratio crosses unity, despite the p value being 0.037, because the former is calculated from a Cox model and the latter from the log-rank. Abbreviations as in Figure 1 . Values are % (n).
Abbreviations as in Table 3 . myocardial blush grade); however, complete ST-segment resolution, enzymatic infarct size, and-most importantlymortality at 1 year (8.3% vs. 9.5%) was not improved (32) . Therefore, it is unlikely that systematic early administration of GPI in the HORIZONS-AMI trial would have had a significant impact on the results overall and in the diabetic subgroup. Study limitations. First, although the present diabetic analysis was a pre-specified substudy, the HORIZONS-AMI trial was not powered for subgroup analysis. As such, despite the large number of diabetic patients enrolled, these results should be considered exploratory and hypothesisgenerating. Second, the open-label design of the study might have introduced potential bias. However, all clinical events were adjudicated by an independent clinical events committee blinded to all procedural medications. Third, as is common in all such substudies, diabetes was diagnosed on admission according to prior history and not by glucose or insulin level testing. It is possible that serial testing of diabetic state might have identified a high-risk diabetic group more prone to benefit with either bivalirudin or heparin plus GPI. This is unlikely, however, given the negative interaction testing from the present analysis and the comparable results with both regimens in patients with insulin treatment.
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Conclusions
The HORIZONS-AMI diabetes substudy demonstrates that, in both high-risk patients with diabetes and nondiabetic patients with STEMI undergoing primary PCI, anticoagulation with bivalirudin monotherapy (with bail-out GPI in 7.6% of patients for refractory thrombotic complications) compared with heparin plus the routine use of a GPI seems to significantly improve 30-day and 1-year net clinical outcomes and survival.
